BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5

Tartof, Sara Y; Slezak, Jeff; Puzniak, Laura; Hong, Vennis; Frankland, Timothy B.; Ackerson, Bradley; Takhar, Harpreet; Ogun, Oluwaseye Ayoola; Simmons, Sarah; Zamparo, Joann M.; Jódar, Luis; McLaughlin, John M.

doi:10.1016/s1473-3099(22)00692-2

Cited by 60 publications

(57 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effectiveness against infection is 12%, 44%, and 88% for those who have received two doses, three doses, and four doses, respectively. [45][46][47] The effectiveness against progression is 50% for those who have received more than two doses. 45 Vaccination coverage rates are considered for each age cohort bucketed by 10 years old, as shown in Figure 6.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of mitigation policies against Omicron BA.5 in Japan: Testing, quarantine, and isolation

Chiba¹

2022

Preprint

View full text Add to dashboard Cite

During the outbreak of Omicron BA.5 in June 2022, strong mitigation policies were still in place in Japan. This paper presents counterfactual experiments regarding testing, the quarantine of positive cases, and isolation, to evaluate the impact of implemented policies. Simulations using an agent-based model showed that high dependence on polymerase chain reaction (PCR) tests and low use of antigen tests exacerbated the outbreak. In addition, the required isolation periods for diagnosed cases were too long; that is, they could have been shortened from 10 to 7 days. Quarantine for those who have had contact with diagnosed patients lowered the epidemic curve; however, this was accompanied by a large number of uninfected quarantined individuals who could not work or go out, which led to economic and social losses. The size of the contribution of each mitigation policy depends on the abundancy of test opportunities. The high positive test rate over this period suggests scarce test opportunities, which led us to conclude that, even without contact tracing and with a shorter duration of isolation and wider use of low-sensitivity antigen tests, the impact of the outbreak could have been made milder.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of mitigation policies against Omicron BA.5 in Japan: Testing, quarantine, and isolation

Chiba¹

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Studies in the US and UK also showed significant VE (60–70%) against BA.4/5-related hospitalization within 3–5 months after the last vaccination (third or fourth dose of the mRNA vaccine). 56 57 58 However, a study reported that significant VE could not be expected 6 months after the third dose or 3 months after the fourth dose of BNT162b2. 58 A study in South Africa conducted an elapsed time-stratified analysis for VE after the third dose of BNT162b2 against BA.4/5-related hospitalization, which showed a decrease in VE over time: 47.7% 3–4 months after the second dose, 26.3% 5–6 months after the second dose, 68.8% 1–2 months after the third dose, and 46.8% 3–4 months after the third dose.…”

Section: Vaccine Effectiveness Against the Omicron Ba4/5 Subvariantsmentioning

confidence: 99%

“… 56 57 58 However, a study reported that significant VE could not be expected 6 months after the third dose or 3 months after the fourth dose of BNT162b2. 58 A study in South Africa conducted an elapsed time-stratified analysis for VE after the third dose of BNT162b2 against BA.4/5-related hospitalization, which showed a decrease in VE over time: 47.7% 3–4 months after the second dose, 26.3% 5–6 months after the second dose, 68.8% 1–2 months after the third dose, and 46.8% 3–4 months after the third dose. 59 The VE against omicron BA.4/5-related hospitalization declined rapidly after the first or second booster, suggesting a limited role of the original SARS-CoV-2-based vaccines.…”

Section: Vaccine Effectiveness Against the Omicron Ba4/5 Subvariantsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Vaccination in Korea: Past, Present, and the Way Forward

et al. 2022

View full text Add to dashboard Cite

Since its first emergence in late 2019, severe acute respiratory syndrome coronavirus-2 has claimed more than 6.5 million lives worldwide and continues to infect hundreds of thousands of people daily. To combat this once-in-a-century disaster, several vaccines have been developed at unprecedented speeds. Novel vaccine platforms (messenger ribonucleic acid vaccines and adenoviral vector vaccines) have played a major role in the current pandemic. In Korea, six vaccines, including a domestically developed recombinant vaccine, have been approved. As in other countries, vaccines have been proven to be safe and highly effective in Korea. However, rare serious adverse events and breakthrough infections have undermined public trust in the vaccines, even while the benefits of vaccination far outweigh the risks. The rise of the omicron variant and the subsequent increase in excess mortality demonstrated that while vaccines are a key component of the pandemic response, it alone can fail without non-pharmaceutical interventions like masking and social distancing. The pandemic of coronavirus disease has revealed both the strengths and weaknesses of our healthcare system and pandemic preparedness. When the next pandemic arrives, improved risk communication and vaccine development should be prioritized. To enable timely vaccine development, it is essential to make strategic and sufficient investments in vaccine research and development.

show abstract

“…Vaccine effectiveness against Omicron after two BNT162b2 doses was modest at 2 to 4 weeks and fell to nearly zero after 6 months or more [7][8][9] . A third and fourth mRNA vaccine booster did improve e cacy against Omicron to 60-70% [10][11][12] , but the durability of protection was less than impressive, with a mean 30-day rate of decay in neutralizing antibody titers of nearly 20% against BA.4/5 13 .…”

Section: Introductionmentioning

confidence: 99%

Active and Passive Immunization of Syrian Hamsters with An Attenuated SARS-CoV-2 Protects against New Variants of Concern

Wang¹,

Stauft

Selvaraj³

et al. 2022

Preprint

View full text Add to dashboard Cite

Detection of secretory antibodies in the airway is highly desirable when evaluating mucosal protection by a vaccine against a respiratory virus like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We show that a single intranasal delivery of an attenuated SARS-CoV-2 (Nsp1-K164A/H165A) induced both mucosal and systemic IgA and IgG in Syrian hamsters. Interestingly, either active or passive immunization of hamsters with Nsp1-K164A/H165A offered protection against heterologous challenge with variants of concern (VOCs) including Delta, Omicron BA.1, and Omicron BA.2.12.1. Among challenged animals, Nsp1-K164A/H165A vaccination specifically reduced viral loads in the respiratory tract and suppressed infection-induced macrophage accumulation and MX1 upregulation in the lung. The absence of variant-specific mucosal and systemic antibodies was associated with breakthrough infections, particularly of the nasal cavity following challenges with Omicron isolates. Together, our study demonstrates that an attenuated nasal vaccine may be developed to boost mucosal immunity against future SARS-CoV-2 VOCs.

show abstract

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5

Cited by 60 publications

References 3 publications

Evaluation of mitigation policies against Omicron BA.5 in Japan: Testing, quarantine, and isolation

Evaluation of mitigation policies against Omicron BA.5 in Japan: Testing, quarantine, and isolation

COVID-19 Vaccination in Korea: Past, Present, and the Way Forward

Active and Passive Immunization of Syrian Hamsters with An Attenuated SARS-CoV-2 Protects against New Variants of Concern

Contact Info

Product

Resources

About